Everything below concerns rodent models. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
=== Prohibited content === Facepunch Studios blacklists servers that are malicious, depict sexual violence, or contain content that is not safe for work but not marked as such. In April 2023, following a Twitter poll with close to 50,000 respondents, the company additionally banned the glorification of Nazism, including the display of swastikas and the Nazi salute.
=== Computing and telecommunications === Adaptive delta modulation, a digital-to-analog data conversion technique Add-drop multiplexer, in optical fiber networks Administrative Template, in Microsoft Windows Group Policy deployment ADM-3A, a computer terminal manufactured by Lear Siegler Application development and maintenance in Lean IT Architecture Development Method, a component of The Open Group Architecture Framework Architecture-driven modernization of legacy software Automated decision-making
== Southern Rhodesians in other theatres == In addition to the main deployments, Southern Rhodesian servicemen served in other theatres of the war. Rhodesian sailors in the Royal, South African and Merchant Navies crewed ships in many parts of the world, including the Indian Ocean, the Arctic and the Pacific. No. 237 (Rhodesia) Squadron operated in Iran and Iraq in 1942–43, guarding oil wells and pipelines and supporting the British Tenth Army. Closer to home, Southern Rhodesian military surveyors contributed to the preliminary planning work for the Allied invasion of Madagascar in May 1942, and landed at Diego Suarez with the invading forces. They remained there long after the Vichy French garrison agreed to an armistice at Ambalavao on 6 November 1942—the last Rhodesian left the island in October 1943.
Sources: en.wikipedia.org
as shown above for one decay. The solution can be found by the integration factor method, where the integrating factor is eλBt. This case is perhaps the most useful since it can derive both the one-decay equation (above) and the equation for multi-decay chains (below) more directly.
== Other uses == VIP style, or VIP Car, a car modification trend Plymouth VIP, a luxury version of the Plymouth Fury (1966-1969) Vacuum insulated panel, a form of thermal insulation consisting of a nearly gas-tight enclosure surrounding a rigid core, from which the air has been evacuated Variable Information Printing, a form of on-demand printing VimpelCom, a stock symbol VIP Ecuador, an Ecuadorian airline VIP Industries, a luggage manufacturer based in India VIP's (restaurant), an American restaurant chain Virgil Partch, a cartoonist who signed his work Vip Virgin Islands Party, a political party in the British Virgin Islands Virology Science and Technology Institute of the Philippines, also known as the Virology Institute of the Philippines (VIP) Vision Inspired by the People, a political party in Belize Visually impaired person, a person with a decreased ability to see
At the end of its 2013 fiscal year, Burger King was the second largest chain of hamburger fast food restaurants in terms of global locations, behind industry bellwether McDonald's, which had 32,400 locations. At the end of 2014, Burger King ranked fourth among US food chains in terms of US sales, behind McDonald's, Starbucks, and Subway. Burger King now has over 12,000 stores worldwide. In January 2024, Restaurant Brands International, the owner of the brand, announced it would purchase the largest franchisee of the chain, Carrols Restaurant Group, for around $1 billion. At the time of the announcement, Carrols had 1,022 Burger King locations (along with 60 Popeyes locations). The goal was to remodel 600 of the restaurants, then sell them back to franchisees over five to seven years. The move represented a departure from the existing model of largely franchising locations.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.